Cargando…

Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study

INTRODUCTION: Ventilator-associated tracheobronchitis (VAT) is associated with increased duration of mechanical ventilation. We hypothesized that, in patients with VAT, antibiotic treatment would be associated with reduced duration of mechanical ventilation. METHODS: We conducted a prospective, rand...

Descripción completa

Detalles Bibliográficos
Autores principales: Nseir, Saad, Favory, Raphaël, Jozefowicz, Elsa, Decamps, Franck, Dewavrin, Florent, Brunin, Guillaume, Di Pompeo, Christophe, Mathieu, Daniel, Durocher, Alain
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2481443/
https://www.ncbi.nlm.nih.gov/pubmed/18454864
http://dx.doi.org/10.1186/cc6890
_version_ 1782157992679964672
author Nseir, Saad
Favory, Raphaël
Jozefowicz, Elsa
Decamps, Franck
Dewavrin, Florent
Brunin, Guillaume
Di Pompeo, Christophe
Mathieu, Daniel
Durocher, Alain
author_facet Nseir, Saad
Favory, Raphaël
Jozefowicz, Elsa
Decamps, Franck
Dewavrin, Florent
Brunin, Guillaume
Di Pompeo, Christophe
Mathieu, Daniel
Durocher, Alain
author_sort Nseir, Saad
collection PubMed
description INTRODUCTION: Ventilator-associated tracheobronchitis (VAT) is associated with increased duration of mechanical ventilation. We hypothesized that, in patients with VAT, antibiotic treatment would be associated with reduced duration of mechanical ventilation. METHODS: We conducted a prospective, randomized, controlled, unblinded, multicenter study. Patients were randomly assigned (1:1) to receive or not receive intravenous antibiotics for 8 days. Patients with ventilator-associated pneumonia (VAP) prior to VAT and those with severe immunosuppression were not eligible. The trial was stopped early because a planned interim analysis found a significant difference in intensive care unit (ICU) mortality. RESULTS: Fifty-eight patients were randomly assigned. Patient characteristics were similar in the antibiotic (n = 22) and no antibiotic (n = 36) groups. Pseudomonas aeruginosa was identified in 32% of VAT episodes. Although no difference was found in mechanical ventilation duration and length of ICU stay, mechanical ventilation-free days were significantly higher (median [interquartile range], 12 [8 to 24] versus 2 [0 to 6] days, P < 0.001) in the antibiotic group than in the no antibiotic group. In addition, subsequent VAP (13% versus 47%, P = 0.011, odds ratio [OR] 0.17, 95% confidence interval [CI] 0.04 to 0.70) and ICU mortality (18% versus 47%, P = 0.047, OR 0.24, 95% CI 0.07 to 0.88) rates were significantly lower in the antibiotic group than in the no antibiotic group. Similar results were found after exclusion of patients with do-not-resuscitate orders and those randomly assigned to the no antibiotic group but who received antibiotics for infections other than VAT or subsequent VAP. CONCLUSION: In patients with VAT, antimicrobial treatment is associated with a greater number of days free of mechanical ventilation and lower rates of VAP and ICU mortality. However, antibiotic treatment has no significant impact on total duration of mechanical ventilation. TRIAL REGISTRATION: ClinicalTrials.gov, number NCT00122057.
format Text
id pubmed-2481443
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-24814432008-07-24 Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study Nseir, Saad Favory, Raphaël Jozefowicz, Elsa Decamps, Franck Dewavrin, Florent Brunin, Guillaume Di Pompeo, Christophe Mathieu, Daniel Durocher, Alain Crit Care Research INTRODUCTION: Ventilator-associated tracheobronchitis (VAT) is associated with increased duration of mechanical ventilation. We hypothesized that, in patients with VAT, antibiotic treatment would be associated with reduced duration of mechanical ventilation. METHODS: We conducted a prospective, randomized, controlled, unblinded, multicenter study. Patients were randomly assigned (1:1) to receive or not receive intravenous antibiotics for 8 days. Patients with ventilator-associated pneumonia (VAP) prior to VAT and those with severe immunosuppression were not eligible. The trial was stopped early because a planned interim analysis found a significant difference in intensive care unit (ICU) mortality. RESULTS: Fifty-eight patients were randomly assigned. Patient characteristics were similar in the antibiotic (n = 22) and no antibiotic (n = 36) groups. Pseudomonas aeruginosa was identified in 32% of VAT episodes. Although no difference was found in mechanical ventilation duration and length of ICU stay, mechanical ventilation-free days were significantly higher (median [interquartile range], 12 [8 to 24] versus 2 [0 to 6] days, P < 0.001) in the antibiotic group than in the no antibiotic group. In addition, subsequent VAP (13% versus 47%, P = 0.011, odds ratio [OR] 0.17, 95% confidence interval [CI] 0.04 to 0.70) and ICU mortality (18% versus 47%, P = 0.047, OR 0.24, 95% CI 0.07 to 0.88) rates were significantly lower in the antibiotic group than in the no antibiotic group. Similar results were found after exclusion of patients with do-not-resuscitate orders and those randomly assigned to the no antibiotic group but who received antibiotics for infections other than VAT or subsequent VAP. CONCLUSION: In patients with VAT, antimicrobial treatment is associated with a greater number of days free of mechanical ventilation and lower rates of VAP and ICU mortality. However, antibiotic treatment has no significant impact on total duration of mechanical ventilation. TRIAL REGISTRATION: ClinicalTrials.gov, number NCT00122057. BioMed Central 2008 2008-05-02 /pmc/articles/PMC2481443/ /pubmed/18454864 http://dx.doi.org/10.1186/cc6890 Text en Copyright © 2008 Nseir et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Nseir, Saad
Favory, Raphaël
Jozefowicz, Elsa
Decamps, Franck
Dewavrin, Florent
Brunin, Guillaume
Di Pompeo, Christophe
Mathieu, Daniel
Durocher, Alain
Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study
title Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study
title_full Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study
title_fullStr Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study
title_full_unstemmed Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study
title_short Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study
title_sort antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2481443/
https://www.ncbi.nlm.nih.gov/pubmed/18454864
http://dx.doi.org/10.1186/cc6890
work_keys_str_mv AT nseirsaad antimicrobialtreatmentforventilatorassociatedtracheobronchitisarandomizedcontrolledmulticenterstudy
AT favoryraphael antimicrobialtreatmentforventilatorassociatedtracheobronchitisarandomizedcontrolledmulticenterstudy
AT jozefowiczelsa antimicrobialtreatmentforventilatorassociatedtracheobronchitisarandomizedcontrolledmulticenterstudy
AT decampsfranck antimicrobialtreatmentforventilatorassociatedtracheobronchitisarandomizedcontrolledmulticenterstudy
AT dewavrinflorent antimicrobialtreatmentforventilatorassociatedtracheobronchitisarandomizedcontrolledmulticenterstudy
AT bruninguillaume antimicrobialtreatmentforventilatorassociatedtracheobronchitisarandomizedcontrolledmulticenterstudy
AT dipompeochristophe antimicrobialtreatmentforventilatorassociatedtracheobronchitisarandomizedcontrolledmulticenterstudy
AT mathieudaniel antimicrobialtreatmentforventilatorassociatedtracheobronchitisarandomizedcontrolledmulticenterstudy
AT durocheralain antimicrobialtreatmentforventilatorassociatedtracheobronchitisarandomizedcontrolledmulticenterstudy
AT antimicrobialtreatmentforventilatorassociatedtracheobronchitisarandomizedcontrolledmulticenterstudy